Recurrence Risk – Medxy AI

Recurrent Severe Hypertensive Disorders in Pregnancy: Evaluating Risks and Outcomes for Future Pregnancies

By MedXY 08/21/2026

This study delineates the significant recurrence risk of severe hypertensive disorders of pregnancy, especially early-onset cases, highlighting implications for patient counseling and management in subsequent pregnancies.

Hematology-Oncology Internal Medicine news

Recurrent Venous Thromboembolism After Isolated Distal DVT: Insights from the RIDTS Trial

By MedXY 07/07/2026

This article reviews the incidence and predictors of recurrent VTE following anticoagulation for isolated distal deep vein thrombosis, highlighting key risk factors and implications for treatment duration and patient management.

Gastroenterology news Oncology

RETREAT Score Stratifies Long-Term Hepatocellular Carcinoma Recurrence Risk After Liver Transplantation in Real-World Practice

By MedXY 06/07/2026

A single-center validation study shows the RETREAT score reliably predicts long-term HCC recurrence after liver transplantation and identifies patients with markedly different recurrence-free and overall survival trajectories.

Diabetes & Endocrinology news Oncology

Calcitonin Doubling Rate Sharpens Postoperative Recurrence Risk Stratification in Medullary Thyroid Carcinoma With Biochemical Persistent Disease

By MedXY 05/04/2026

In medullary thyroid carcinoma with biochemical persistent disease after surgery, an early postoperative calcitonin doubling rate of at least 0.3/year strongly identified patients at higher recurrence risk and may help tailor surveillance intensity.

General Surgery news Oncology

Beyond Nodal Status: A New Risk Score Predicts Recurrence in Lymph Node-Negative Pancreatic Neuroendocrine Tumors

By MedXY 12/22/2025

A multi-center study in JAMA Surgery introduces a validated 13-point risk score to identify recurrence risk in LN-negative PanNET patients, revealing that tumor size, grade, and lymphovascular invasion are critical prognostic drivers even when nodes are clear.